ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance

During the past decade, more than 10 targetable oncogenic driver genes have been validated in non-small cell lung cancer (NSCLC). Anaplastic lymphoma kinase (ALK) and ROS1 kinase are two new driver genes implicated in ALK- and ROS1-rearranged NSCLC. Inhibition of ALK and ROS1 by crizotinib has been...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Ye, Mingxiang, Zhang, Xinxin, Li, Nan, Zhang, Yong, Jing, Pengyu, Chang, Ning, Wu, Jianxiong, Ren, Xinling, Zhang, Jian
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4914285/
https://ncbi.nlm.nih.gov/pubmed/26802023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6935
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados